A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.
Public ClinicalTrials.gov record NCT04239014. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized, Multi-Centre Study to Investigate the Efficacy and Tolerability of a Second Maintenance Treatment in Patients With Platinum Sensitive Relapsed Epithelial Ovarian Cancer, Who Have Previously Received PARP Inhibitor Maintenance Treatment
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To investigate the effectiveness and tolerability of a second maintenance treatment in participants with platinum-sensitivity relapsed (PSR) epithelial ovarian cancer, who have previously received PARPi maintenance treatment and who have benefit (complete response \[CR\] or partial response \[PR\]) or stable disease (SD) from further platinum based chemotherapy.
Study identification
- NCT ID
- NCT04239014
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 7, 2020 (Actual)
- Primary completion
- Jan 25, 2021 (Actual)
- Completion
- Jan 25, 2021 (Actual)
- Last update posted
- Mar 10, 2021
2020 – 2021
United States locations
- U.S. sites
- 22
- U.S. states
- 15
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Anchorage | Alaska | 99508 | — |
| Research Site | La Jolla | California | 92093-0021 | — |
| Research Site | Long Beach | California | 90806 | — |
| Research Site | Los Angeles | California | 90048 | — |
| Research Site | West Hollywood | California | 97210 | — |
| Research Site | Hartford | Connecticut | 06106 | — |
| Research Site | Tampa | Florida | 33612 | — |
| Research Site | Atlanta | Georgia | 30342 | — |
| Research Site | Louisville | Kentucky | 40202 | — |
| Research Site | Covington | Louisiana | 70433 | — |
| Research Site | Florham Park | New Jersey | 07932 | — |
| Research Site | Teaneck | New Jersey | 07666 | — |
| Research Site | Cleveland | Ohio | 44106 | — |
| Research Site | Oklahoma City | Oklahoma | 73104 | — |
| Research Site | Tulsa | Oklahoma | 74146 | — |
| Research Site | Portland | Oregon | 97210 | — |
| Research Site | Abington | Pennsylvania | 19001 | — |
| Research Site | Philadelphia | Pennsylvania | 19104 | — |
| Research Site | Sioux Falls | South Dakota | 57105-1599 | — |
| Research Site | Sioux Falls | South Dakota | 57105 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04239014, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 10, 2021 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04239014 live on ClinicalTrials.gov.